Status:
COMPLETED
BetaPlus Survey - Observational Study to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon® by Using Elements of the BetaPlus Program
Lead Sponsor:
Bayer
Conditions:
Relapsing Remitting MS (RRMS)
Secondary Progressive MS (SPMS)
Eligibility:
All Genders
18+ years
Brief Summary
This is an observational survey to assess the factors that influence adherence to Betaferon therapy in multiple sclerosis patients using elements of the BetaPlus support program, including the nurse s...
Eligibility Criteria
Inclusion
- Relapsing-remitting MS (RRMS) or secondary-progressive MS (SPMS)
- Previous treatment with disease modifying drugs
- Adjustment of disease modifying treatment necessary at the discretion of the investigator
- Switch to Betaferon at least 1 month but not longer than 3 months prior to inclusion
Exclusion
- Patients not fulfilling the indications in the local prescribing information
- Refusal to sign inform consent
Key Trial Info
Start Date :
April 1 2004
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2009
Estimated Enrollment :
1077 Patients enrolled
Trial Details
Trial ID
NCT01233245
Start Date
April 1 2004
End Date
June 1 2009
Last Update
November 15 2012
Active Locations (15)
Enter a location and click search to find clinical trials sorted by distance.
1
Many Locations, Czechia
2
Many Locations, France
3
Many Locations, Germany
4
Many Locations, Iran